Drew Hansen

Emergent BioSolutions Inc.’s $135 million deal struck late last month to manufacture Johnson & Johnson’s Covid-19 vaccine candidate isn’t just a big financial win for the company — it’s also a key geopolitical move in the race to defeat the virus.

According to The New York Times, the Department of Health and Human Services made sure Johnson & Johnson (NYSE: JNJ) — which is headquartered in New Jersey but has its research based in the Netherlands — joined a manufacturing partnership with the Maryland-based biotech to ensure the earliest available large batches of the vaccine, if approved, are produced stateside.

 

money

Grants for Technology Product Development

Market-driven new technology and innovation leads to new products and new jobs. Creating jobs in innovative Maryland companies is what the Maryland Industrial Partnerships (MIPS) program has been doing for 32 years: bringing the inventive minds and extensive laboratory resources of the University System of Maryland (USM) to bear on creating the new products that feed the growth of Maryland businesses. Since the program’s inception in 1987, MIPS–enabled products have generated sales of $40 B.  MIPS is nationally recognized by the U.S. Small Business Administration as a model program for best practices in transferring technology and is a proven program that contributes significantly to job creation and high tech product development in Maryland.

 

NewImage

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.

 

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). (CDC/Alissa Eckert, MS)

Johns Hopkins University has been given $200,000 in federal funds to support its global COVID-19 tracker that has become the preeminent resource worldwide for tracking the spread of the coronavirus.

Democratic Senators Ben Cardin and Chris Van Hollen and Democratic Representatives Dutch Ruppersberger and John P. Sarbanes said the federal funds will be disbursed through the National Science Foundation Rapid Response Research grant program. The federal coronavirus stimulus package, under the CARES Act, allocated $75 million to the foundation to fund efforts that prevent, prepare for and respond to the coronavirus, domestically or internationally.

 

Roche

BASEL: Roche Holding received emergency use approval from the US Food and Drug Administration (FDA) for an antibody test to help determine if people have ever been infected with the coronavirus, the Swiss drugmaker said on Sunday (May 3).

Governments, businesses and individuals are seeking such blood tests, to help them learn more about who may have had the disease, who may have some immunity and to potentially craft strategies to end lockdowns that have battered global economies.

 

Meet the minds behind the Johns Hopkins coronavirus map

Beth Blauer and Dr. Jennifer Nuzzo, two key members of the Johns Hopkins team that is tracking every confirmed coronavirus case, tell Brian Stelter how they do it, what the numbers do and don't reveal, and why people can have confidence in the data, even though it is incomplete. With regards to the death toll, "we may see that the true number is actually larger than what's been reported," Nuzzo says, "not the other way around."

 

Lance and gmu logo

Scientists at George Mason University are working to develop an easy-to-administer COVID-19 antibody test, which could mean using a simple swab in the mouth for saliva.

Dr. Lance Liotta works for the Applied Proteomics and Molecular Medicine Center at GMU. He said they’ve been working on saliva testing for many years and already had a collection device that would work.

“We thought let's apply our expertise on that topic to that new challenge,” Liotta said.

Image: https://www.nbcwashington.com

NewImage

The Association of University Research Parks (AURP), a global nonprofit membership organization serving the university and institutional research parks community, today announced its BIO Health Caucus will take place June 3-4, 2020 in a digital environment. AURP’s BIO Health Caucus represents anchor life science institutions building communities of health innovations in the U.S and around the world.

AURP’s 2020 BIO Health Caucus explores trends in life science research, opportunity zone funding, the marriage of life science and philanthropy, and finding funding for projects and facilities during a global pandemic. At this digital event, attendees will discover the role that biomedical clusters play in innovation ecosystems and translating discoveries from lab to market.

Image: Joel Marcus

NewImage

The Association of University Research Parks (AURP), a global nonprofit membership organization serving the university and institutional research parks community, today announced its BIO Health Caucus will take place June 3-4, 2020 in a digital environment. AURP’s BIO Health Caucus represents anchor life science institutions building communities of health innovations in the U.S and around the world.

AURP’s 2020 BIO Health Caucus explores trends in life science research, opportunity zone funding, the marriage of life science and philanthropy, and finding funding for projects and facilities during a global pandemic. At this digital event, attendees will discover the role that biomedical clusters play in innovation ecosystems and translating discoveries from lab to market.

Image: Joel Marcus

Larry Hogan

Larry Hogan has got another of his ideas, and this one cracks him up. “I’m gonna call Pence!” says Hogan, startling his chief of staff, Matthew Clark, who sits across a large, round faux-wood table. Hogan, the Republican governor of Maryland, is meeting with his coronavirus command team, a skeleton crew of state officials still reporting to the capitol in Annapolis. The conference rooms are all too narrow, so they are gathered in a cavernous event room, seated in alternate chairs to maintain social distancing. Hogan, a ruddy 63-year-old with jug-handle ears, has in front of him a dispenser of hand sanitizer, a can of Diet Coke and a starfish-shaped conference-call speaker.

Image: https://governor.maryland.gov/governor-larry-hogan/

NewImage

Sponsored by the Division of Strategic Partnerships and Applied Research, the StarTUp Accelerator supports student and local business ventures in an intensive eight-week, cohort-based fellowship where start-up businesses take residency and work in a collaborative space to accelerate their ventures. The inaugural cohort is a diverse group that includes two student-based ventures, a 100% halal-certified consumer cosmetics brand, a sports betting game from recent TU grads, and ventures from current TU faculty.

 

NewImage

Sykesville, MD; March 13, 2020- Noble Life Sciences is excited to announce renewal of full accreditation from Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. Noble Life Sciences has held full AAALAC accreditation since October 10, 1989. Accredited contract research organizations (CROs) are re-evaluated every three years through an extensive internal review and on-site inspection conducted by members of AAALAC accreditation council and reviewed by the full council to determine accreditation status.

 

NewImage

AstraZeneca will oversee global development, manufacturing, and distribution of the COVID-19 vaccine candidate that was created by researchers at University of Oxford, and is now being studied in a human clinical trial launched last week, the partners said today.

AstraZeneca, the University, and its spinout company Vaccitech—which has joint rights to the platform technology behind the vaccine candidate, ChAdOx1 nCoV-19—said they will start work immediately while hammering out final terms of their collaboration agreement. The partnership is designed to enable rapid production and distribution of the vaccine should it prove effective in clinical studies.

Image: AstraZeneca will oversee global development, manufacturing, and distribution of the COVID-19 vaccine candidate that was created by researchers at University of Oxford, and is now being studied in a human clinical trial launched last week. (University of Oxford)

Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large scale distribution of the COVID 19 vaccine candidate Vaccitech

Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.

The partnership is to begin immediately with the final terms being agreed in the coming weeks. This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective. The vaccine candidate was developed by the University’s Jenner Institute who began trials in humans last week jointly with the University’s Oxford Vaccine Group.

 

200428 force april 28 en pdf

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a randomized, doubleblind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients with severe pneumonia.

The primary objective of this investigator-sponsored trial, named FORCEa , is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).